北京医学
北京醫學
북경의학
BEIJING MEDICAL JOURNAL
2014年
11期
920-922
,共3页
房纯%张治国%韩磊%苗劲蔚
房純%張治國%韓磊%苗勁蔚
방순%장치국%한뢰%묘경위
上皮性卵巢癌%早期%无瘤生存率%生存率%化疗
上皮性卵巢癌%早期%無瘤生存率%生存率%化療
상피성란소암%조기%무류생존솔%생존솔%화료
Epithelia ovarian cancer%Early stage%Disease-free survival rate (DFS)%Overall survival rate (OS)%Chemotherapy
目的：比较不同化疗疗程对早期卵巢上皮癌患者生存率和无瘤生存率的影响。方法180例患者按预后风险因素及化疗疗程分组，无瘤生存率及生存率采用Kaplan-Meier法估算，采用Log-Rank检验进行比较。结果≤4疗程（Ⅰ组）及﹥4疗程（Ⅱ组）5年总生存率（5-OS）、2年无瘤生存率（2-DFS）及5年无瘤生存率（5-DFS）分别为54.1%、51.6%、47.8%，48.3%、41.8%、40.0%；两组5-OS、2-DFS 及5-DFS 的差异均无统计学意义（P=0.926，P=0.713）。高危组和低危组患者5-OS、2-DFS 及5-DFS 分别为45.6%、84.7%，38.5%、93.5%，32.9%、77.5%；两组5-OS、2-DFS及5-DFS差异有统计学意义（P均=0.000）。高危组中≤4疗程（A1组）及﹥4疗程（A2组）5-OS、2-DFS及5-DFS分别为39.6%、48.5%，26.8%、43.7%，26.8%、36.0%；两组5-OS差异无统计学意义（P=0.314），A1组2-DFS及5-DFS均低于A2组（P=0.011）。低危组中≤4疗程化疗及﹥4疗程5-OS、2-DFS及5-DFS分别为85.1%、83.3%，95.0%、90.9%，77.7%、77.9%；两组5-OS、2-DFS及5-DFS差异无统计学意义（P＞0.5）。结论高危组早期上皮性卵巢癌患者术后予大于4疗程化疗可提高其无瘤生存率。
目的：比較不同化療療程對早期卵巢上皮癌患者生存率和無瘤生存率的影響。方法180例患者按預後風險因素及化療療程分組，無瘤生存率及生存率採用Kaplan-Meier法估算，採用Log-Rank檢驗進行比較。結果≤4療程（Ⅰ組）及﹥4療程（Ⅱ組）5年總生存率（5-OS）、2年無瘤生存率（2-DFS）及5年無瘤生存率（5-DFS）分彆為54.1%、51.6%、47.8%，48.3%、41.8%、40.0%；兩組5-OS、2-DFS 及5-DFS 的差異均無統計學意義（P=0.926，P=0.713）。高危組和低危組患者5-OS、2-DFS 及5-DFS 分彆為45.6%、84.7%，38.5%、93.5%，32.9%、77.5%；兩組5-OS、2-DFS及5-DFS差異有統計學意義（P均=0.000）。高危組中≤4療程（A1組）及﹥4療程（A2組）5-OS、2-DFS及5-DFS分彆為39.6%、48.5%，26.8%、43.7%，26.8%、36.0%；兩組5-OS差異無統計學意義（P=0.314），A1組2-DFS及5-DFS均低于A2組（P=0.011）。低危組中≤4療程化療及﹥4療程5-OS、2-DFS及5-DFS分彆為85.1%、83.3%，95.0%、90.9%，77.7%、77.9%；兩組5-OS、2-DFS及5-DFS差異無統計學意義（P＞0.5）。結論高危組早期上皮性卵巢癌患者術後予大于4療程化療可提高其無瘤生存率。
목적：비교불동화료료정대조기란소상피암환자생존솔화무류생존솔적영향。방법180례환자안예후풍험인소급화료료정분조，무류생존솔급생존솔채용Kaplan-Meier법고산，채용Log-Rank검험진행비교。결과≤4료정（Ⅰ조）급﹥4료정（Ⅱ조）5년총생존솔（5-OS）、2년무류생존솔（2-DFS）급5년무류생존솔（5-DFS）분별위54.1%、51.6%、47.8%，48.3%、41.8%、40.0%；량조5-OS、2-DFS 급5-DFS 적차이균무통계학의의（P=0.926，P=0.713）。고위조화저위조환자5-OS、2-DFS 급5-DFS 분별위45.6%、84.7%，38.5%、93.5%，32.9%、77.5%；량조5-OS、2-DFS급5-DFS차이유통계학의의（P균=0.000）。고위조중≤4료정（A1조）급﹥4료정（A2조）5-OS、2-DFS급5-DFS분별위39.6%、48.5%，26.8%、43.7%，26.8%、36.0%；량조5-OS차이무통계학의의（P=0.314），A1조2-DFS급5-DFS균저우A2조（P=0.011）。저위조중≤4료정화료급﹥4료정5-OS、2-DFS급5-DFS분별위85.1%、83.3%，95.0%、90.9%，77.7%、77.9%；량조5-OS、2-DFS급5-DFS차이무통계학의의（P＞0.5）。결론고위조조기상피성란소암환자술후여대우4료정화료가제고기무류생존솔。
Objective To compare 5-year overall survival rate (5-OS) and disease-free survival rate (DFS) on early stage epithelia ovarian cancer patients with different chemotherapy cycles. Methods One hundred and eighty patients were divided into different groups based on the cycles of chemotherapy and prognostic risk factors. SPSS13.0 Kaplan-Meier survival analyses were performed to estimate 5-OS and DFS. Log-rank test was employed to compare the differences in 5-OS and DFS. Results The 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy was 54.1%, 51.6%, 47.8%and 48.3%, 41.8%, 40.0%. The 5-OS, the 2-DFS and 5-DFS with different cy-cles of chemotherapy was not significantly different between the two groups (P=0.926, P=0.713). The 5-OS, 2-DFS and 5-DFS of the high-risk group and the low-risk group were 45.6%, 84.7%, 38.5% and 93.5%, 32.9%, 77.5%. The 5-OS, the 2-DFS and 5-DFS with different cycles of chemotherapy were significantly different between the two groups (P=0.000, P= 0.000). In the high-risk group, the 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy was 39.6%, 48.5%, 26.8% and 43.7%, 26.8%, 36.0%. The 5-OS was not significantly different be-tween the two groups (P= 0.314). The 2-DFS and 5-DFS of more than 4 chemotherapy was higher (P= 0.011). In the low-risk group, the 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy were 85.1%, 83.3%, 95.0% and 90.9%, 77.7%, 77.9%. The 5-OS, the 2-DFS and 5-DFS were not significantly different between the two groups (P= 0.596, P= 0.760). Conclusion More than 4 cycles of chemotherapy can improve the dis-ease-free survival rate in high-risk early stage epithelial ovarian cancer.
